[B01AD01, streptokinase, The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Ursodeoxycholic acid.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC01, sulfamethoxazole, Ursodeoxycholic acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ursodeoxycholic acid.]
[L02BA01, tamoxifen, Tamoxifen may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Ursodeoxycholic acid.]
[B01AC05, ticlopidine, The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ursodeoxycholic acid.]
[P01AB02, tinidazole, Ursodeoxycholic acid may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[C01DX11, trapidil, The risk or severity of adverse effects can be increased when Trapidil is combined with Ursodeoxycholic acid.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Ursodeoxycholic acid.]
[B01AD04, urokinase, The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Ursodeoxycholic acid.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Ursodeoxycholic acid.]
[B01AC24, ticagrelor, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ursodeoxycholic acid.]
[L01CA01, vinblastine, Ursodeoxycholic acid may decrease the excretion rate of Vinblastine which could result in a higher serum level.]
[L01CA02, vincristine, Ursodeoxycholic acid may decrease the excretion rate of Vincristine which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Ursodeoxycholic acid.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[J05AE02, indinavir, Ursodeoxycholic acid may decrease the excretion rate of Indinavir which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.]
[G03AC10, drospirenone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ursodeoxycholic acid.]
[C07AB03, atenolol, Ursodeoxycholic acid may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[S01FA01, atropine, Ursodeoxycholic acid may decrease the excretion rate of Atropine which could result in a higher serum level.]
[B01AX01, defibrotide, The risk or severity of adverse effects can be increased when Defibrotide is combined with Ursodeoxycholic acid.]
[J05AE04, nelfinavir, Ursodeoxycholic acid may decrease the excretion rate of Nelfinavir which could result in a higher serum level.]
[B01AF02, apixaban, The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Ursodeoxycholic acid.]
[M04AB03, benzbromarone, Ursodeoxycholic acid may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA03, cholic acid, Ursodeoxycholic acid may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AE03, argatroban, The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Ursodeoxycholic acid.]
[C10AB02, bezafibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Bezafibrate.]
[B01AC26, vorapaxar, The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ursodeoxycholic acid.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Ursodeoxycholic acid.]
[B01AA01, dicumarol, The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Ursodeoxycholic acid.]
[B01AF03, edoxaban, The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Ursodeoxycholic acid.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Ursodeoxycholic acid.]
[B01AC25, cangrelor, The risk or severity of adverse effects can be increased when Cangrelor is combined with Ursodeoxycholic acid.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BX02, aluminum chlorohydrate, Aluminum chlorohydrate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Ursodeoxycholic acid is combined with Obeticholic acid.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Ursodeoxycholic acid.]
[J05AG03, efavirenz, Ursodeoxycholic acid may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[R03BA02, budesonide, Ursodeoxycholic acid may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of adverse effects can be increased when Buflomedil is combined with Ursodeoxycholic acid.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ursodeoxycholic acid.]
[B01AC23, cilostazol, The risk or severity of adverse effects can be increased when Cilostazol is combined with Ursodeoxycholic acid.]
[C10AB08, ciprofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Ciprofibrate.]
[J01FA09, clarithromycin, Ursodeoxycholic acid may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DC04, cefaclor, Ursodeoxycholic acid may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[G03DB05, demegestone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Demegestone.]
[G03AC09, desogestrel, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Desogestrel.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Ursodeoxycholic acid.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Ursodeoxycholic acid.]
[G03DB08, dienogest, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Dienogest.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Ursodeoxycholic acid.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Ursodeoxycholic acid.]
[B01AE02, lepirudin, The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.]
[L01FX15, belantamab mafodotin, Ursodeoxycholic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB09, etofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Etofibrate.]
[S01JA01, fluorescein, Ursodeoxycholic acid may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[A10BB12, glimepiride, Ursodeoxycholic acid may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Ursodeoxycholic acid.]
[B01AD11, tenecteplase, The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Ursodeoxycholic acid.]
[C10AB01, clofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Clofibrate.]
[A05BA08, glycyrrhizic acid, Ursodeoxycholic acid may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Indobufen is combined with Ursodeoxycholic acid.]
[B01AB12, bemiparin, The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Ursodeoxycholic acid.]
[L01EA01, imatinib, Ursodeoxycholic acid may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[R06AX13, loratadine, Ursodeoxycholic acid may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C10AA07, rosuvastatin, Ursodeoxycholic acid may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[L01DB02, daunorubicin, Ursodeoxycholic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AX06, nefazodone, Ursodeoxycholic acid may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[B01AX05, fondaparinux, The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Ursodeoxycholic acid.]
[S03BA01, dexamethasone, Dexamethasone may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ursodeoxycholic acid.]
[S01BC03, diclofenac, Ursodeoxycholic acid may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[L02AA01, diethylstilbestrol, Ursodeoxycholic acid may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.]
[C08CA03, isradipine, Ursodeoxycholic acid may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[C01AA05, digoxin, Ursodeoxycholic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, Ursodeoxycholic acid may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Ursodeoxycholic acid may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[J05AE08, atazanavir, Ursodeoxycholic acid may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ursodeoxycholic acid.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Ursodeoxycholic acid.]
[P03AA04, disulfiram, Ursodeoxycholic acid may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[C01EB18, ranolazine, Ursodeoxycholic acid may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[L01DB01, doxorubicin, Ursodeoxycholic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[C10AA01, simvastatin, Ursodeoxycholic acid may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of adverse effects can be increased when Triflusal is combined with Ursodeoxycholic acid.]
[C05CA04, troxerutin, The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Ursodeoxycholic acid.]
[B01AD03, anistreplase, The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Ursodeoxycholic acid.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Ursodeoxycholic acid.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[G03CA03, estradiol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estradiol.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[R06AX11, astemizole, Ursodeoxycholic acid may decrease the excretion rate of Astemizole which could result in a higher serum level.]
[R06AX12, terfenadine, Ursodeoxycholic acid may decrease the excretion rate of Terfenadine which could result in a higher serum level.]
[N06AB08, fluvoxamine, Ursodeoxycholic acid may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C10AA03, pravastatin, Ursodeoxycholic acid may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding and bruising can be increased when Dextran is combined with Ursodeoxycholic acid.]
[C08CA02, felodipine, Ursodeoxycholic acid may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding and bruising can be increased when Fibrinolysin is combined with Ursodeoxycholic acid.]
[J01CF05, floxacillin, Ursodeoxycholic acid may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[D10AX01, aluminum chloride, Aluminum chloride can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB04, gemfibrozil, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Gemfibrozil.]
[G03XA02, gestrinone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Gestrinone.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[A10BB07, glipizide, Ursodeoxycholic acid may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Ursodeoxycholic acid.]
[C09CA01, losartan, Ursodeoxycholic acid may decrease the excretion rate of Losartan which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding and bruising can be increased when Heparin is combined with Ursodeoxycholic acid.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Nimesulide is combined with Ursodeoxycholic acid.]
[S01XA07, aluminum potassium sulfate, Potassium alum can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05CB02, sodium citrate, The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Ursodeoxycholic acid.]
[L01CD01, paclitaxel, Ursodeoxycholic acid may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
[S01BC01, indomethacin, Ursodeoxycholic acid may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C10AA06, cerivastatin, Ursodeoxycholic acid may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of adverse effects can be increased when Anagrelide is combined with Ursodeoxycholic acid.]
[B01AE06, bivalirudin, The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Ursodeoxycholic acid.]
[A07BC02, kaolin, Kaolin can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Ursodeoxycholic acid.]
[B01AC22, prasugrel, The risk or severity of adverse effects can be increased when Prasugrel is combined with Ursodeoxycholic acid.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[D10AX04, aluminum oxide, Aluminum oxide can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Levonorgestrel.]
[C10AA02, lovastatin, Ursodeoxycholic acid may decrease the excretion rate of Lovastatin which could result in a higher serum level.]
[G03DC03, lynestrenol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Lynestrenol.]
[B01AB06, nadroparin, The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Ursodeoxycholic acid.]
[B01AB05, enoxaparin, The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Ursodeoxycholic acid.]
[B01AB04, dalteparin, The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Ursodeoxycholic acid.]
[B01AB07, parnaparin, The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Ursodeoxycholic acid.]
[G03XB01, mifepristone, Ursodeoxycholic acid may decrease the excretion rate of Mifepristone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Ursodeoxycholic acid.]
[M02AA12, naproxen, Ursodeoxycholic acid may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[A10BX02, repaglinide, Ursodeoxycholic acid may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[B01AC17, tirofiban, The risk or severity of adverse effects can be increased when Tirofiban is combined with Ursodeoxycholic acid.]
[C09CA07, telmisartan, Ursodeoxycholic acid may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[C08CA04, nicardipine, Ursodeoxycholic acid may decrease the excretion rate of Nicardipine which could result in a higher serum level.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C08CA08, nitrendipine, Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XE01, nitrofurantoin, Ursodeoxycholic acid may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[G03DC02, norethindrone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Norethisterone.]
[G03AC07, norgestrienone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Norgestrienone.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AC16, eptifibatide, The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ursodeoxycholic acid.]
[B01AB08, reviparin, The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Ursodeoxycholic acid.]
[S02AA16, ofloxacin, Ursodeoxycholic acid may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Ursodeoxycholic acid.]
[B01AD09, ancrod, The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Ursodeoxycholic acid.]
[B01AB09, danaparoid, The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Ursodeoxycholic acid.]
[G03DB06, chlormadinone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Chlormadinone.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ursodeoxycholic acid.]
[B01AA02, phenindione, The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Ursodeoxycholic acid.]
[N03AA02, phenobarbital, Phenobarbital may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Ursodeoxycholic acid.]
[C10AA05, atorvastatin, Ursodeoxycholic acid may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J05AE01, saquinavir, Ursodeoxycholic acid may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Ursodeoxycholic acid.]
[S01XA13, alteplase, The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Ursodeoxycholic acid.]
[A10BG02, rosiglitazone, Ursodeoxycholic acid may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[J05AE03, ritonavir, Ursodeoxycholic acid may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[C10AA08, pitavastatin, Ursodeoxycholic acid may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C10AB05, fenofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibrate.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ursodeoxycholic acid.]
[C01BA01, quinidine, Quinidine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C03DA01, spironolactone, Ursodeoxycholic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Ursodeoxycholic acid.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC01, sulfamethoxazole, Ursodeoxycholic acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ursodeoxycholic acid.]
[L02BA01, tamoxifen, Tamoxifen may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Ursodeoxycholic acid.]
[B01AC05, ticlopidine, The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ursodeoxycholic acid.]
[P01AB02, tinidazole, Ursodeoxycholic acid may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[C01DX11, trapidil, The risk or severity of adverse effects can be increased when Trapidil is combined with Ursodeoxycholic acid.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Ursodeoxycholic acid.]
[B01AD04, urokinase, The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Ursodeoxycholic acid.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Ursodeoxycholic acid.]
[B01AC24, ticagrelor, The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ursodeoxycholic acid.]
[L01CA01, vinblastine, Ursodeoxycholic acid may decrease the excretion rate of Vinblastine which could result in a higher serum level.]
[L01CA02, vincristine, Ursodeoxycholic acid may decrease the excretion rate of Vincristine which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Ursodeoxycholic acid.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[J05AE02, indinavir, Ursodeoxycholic acid may decrease the excretion rate of Indinavir which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.]
[G03AC10, drospirenone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ursodeoxycholic acid.]
[C07AB03, atenolol, Ursodeoxycholic acid may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[S01FA01, atropine, Ursodeoxycholic acid may decrease the excretion rate of Atropine which could result in a higher serum level.]
[B01AX01, defibrotide, The risk or severity of adverse effects can be increased when Defibrotide is combined with Ursodeoxycholic acid.]
[J05AE04, nelfinavir, Ursodeoxycholic acid may decrease the excretion rate of Nelfinavir which could result in a higher serum level.]
[B01AF02, apixaban, The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Ursodeoxycholic acid.]
[M04AB03, benzbromarone, Ursodeoxycholic acid may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA03, cholic acid, Ursodeoxycholic acid may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AE03, argatroban, The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Ursodeoxycholic acid.]
[C10AB02, bezafibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Bezafibrate.]
[B01AC26, vorapaxar, The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ursodeoxycholic acid.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Ursodeoxycholic acid.]
[B01AA01, dicumarol, The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Ursodeoxycholic acid.]
[B01AF03, edoxaban, The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Ursodeoxycholic acid.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Ursodeoxycholic acid.]
[B01AC25, cangrelor, The risk or severity of adverse effects can be increased when Cangrelor is combined with Ursodeoxycholic acid.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BX02, aluminum chlorohydrate, Aluminum chlorohydrate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Ursodeoxycholic acid is combined with Obeticholic acid.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Ursodeoxycholic acid.]
[J05AG03, efavirenz, Ursodeoxycholic acid may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[R03BA02, budesonide, Ursodeoxycholic acid may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of adverse effects can be increased when Buflomedil is combined with Ursodeoxycholic acid.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ursodeoxycholic acid.]
[B01AC23, cilostazol, The risk or severity of adverse effects can be increased when Cilostazol is combined with Ursodeoxycholic acid.]
[C10AB08, ciprofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Ciprofibrate.]
[J01FA09, clarithromycin, Ursodeoxycholic acid may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DC04, cefaclor, Ursodeoxycholic acid may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[G03DB05, demegestone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Demegestone.]
[G03AC09, desogestrel, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Desogestrel.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Ursodeoxycholic acid.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Ursodeoxycholic acid.]
[G03DB08, dienogest, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Dienogest.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Ursodeoxycholic acid.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Ursodeoxycholic acid.]
[B01AE02, lepirudin, The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.]
[L01FX15, belantamab mafodotin, Ursodeoxycholic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB09, etofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Etofibrate.]
[S01JA01, fluorescein, Ursodeoxycholic acid may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[A10BB12, glimepiride, Ursodeoxycholic acid may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Ursodeoxycholic acid.]
[B01AD11, tenecteplase, The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Ursodeoxycholic acid.]
[C10AB01, clofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Clofibrate.]
[A05BA08, glycyrrhizic acid, Ursodeoxycholic acid may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Indobufen is combined with Ursodeoxycholic acid.]
[B01AB12, bemiparin, The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Ursodeoxycholic acid.]
[L01EA01, imatinib, Ursodeoxycholic acid may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[R06AX13, loratadine, Ursodeoxycholic acid may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C10AA07, rosuvastatin, Ursodeoxycholic acid may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[L01DB02, daunorubicin, Ursodeoxycholic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AX06, nefazodone, Ursodeoxycholic acid may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[B01AX05, fondaparinux, The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Ursodeoxycholic acid.]
[S03BA01, dexamethasone, Dexamethasone may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ursodeoxycholic acid.]
[S01BC03, diclofenac, Ursodeoxycholic acid may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[L02AA01, diethylstilbestrol, Ursodeoxycholic acid may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.]
[C08CA03, isradipine, Ursodeoxycholic acid may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[C01AA05, digoxin, Ursodeoxycholic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, Ursodeoxycholic acid may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Ursodeoxycholic acid may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[J05AE08, atazanavir, Ursodeoxycholic acid may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ursodeoxycholic acid.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Ursodeoxycholic acid.]
[P03AA04, disulfiram, Ursodeoxycholic acid may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[C01EB18, ranolazine, Ursodeoxycholic acid may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[L01DB01, doxorubicin, Ursodeoxycholic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[C10AA01, simvastatin, Ursodeoxycholic acid may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of adverse effects can be increased when Triflusal is combined with Ursodeoxycholic acid.]
[C05CA04, troxerutin, The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Ursodeoxycholic acid.]
[B01AD03, anistreplase, The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Ursodeoxycholic acid.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Ursodeoxycholic acid.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[G03CA03, estradiol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estradiol.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[R06AX11, astemizole, Ursodeoxycholic acid may decrease the excretion rate of Astemizole which could result in a higher serum level.]
[R06AX12, terfenadine, Ursodeoxycholic acid may decrease the excretion rate of Terfenadine which could result in a higher serum level.]
[N06AB08, fluvoxamine, Ursodeoxycholic acid may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C10AA03, pravastatin, Ursodeoxycholic acid may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding and bruising can be increased when Dextran is combined with Ursodeoxycholic acid.]
[C08CA02, felodipine, Ursodeoxycholic acid may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding and bruising can be increased when Fibrinolysin is combined with Ursodeoxycholic acid.]
[J01CF05, floxacillin, Ursodeoxycholic acid may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[D10AX01, aluminum chloride, Aluminum chloride can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB04, gemfibrozil, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Gemfibrozil.]
[G03XA02, gestrinone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Gestrinone.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[A10BB07, glipizide, Ursodeoxycholic acid may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Ursodeoxycholic acid.]
[C09CA01, losartan, Ursodeoxycholic acid may decrease the excretion rate of Losartan which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding and bruising can be increased when Heparin is combined with Ursodeoxycholic acid.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Nimesulide is combined with Ursodeoxycholic acid.]
[S01XA07, aluminum potassium sulfate, Potassium alum can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05CB02, sodium citrate, The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Ursodeoxycholic acid.]
[L01CD01, paclitaxel, Ursodeoxycholic acid may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
[S01BC01, indomethacin, Ursodeoxycholic acid may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C10AA06, cerivastatin, Ursodeoxycholic acid may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of adverse effects can be increased when Anagrelide is combined with Ursodeoxycholic acid.]
[B01AE06, bivalirudin, The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Ursodeoxycholic acid.]
[A07BC02, kaolin, Kaolin can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Ursodeoxycholic acid.]
[B01AC22, prasugrel, The risk or severity of adverse effects can be increased when Prasugrel is combined with Ursodeoxycholic acid.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[D10AX04, aluminum oxide, Aluminum oxide can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Levonorgestrel.]
[C10AA02, lovastatin, Ursodeoxycholic acid may decrease the excretion rate of Lovastatin which could result in a higher serum level.]
[G03DC03, lynestrenol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Lynestrenol.]
[B01AB06, nadroparin, The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Ursodeoxycholic acid.]
[B01AB05, enoxaparin, The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Ursodeoxycholic acid.]
[B01AB04, dalteparin, The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Ursodeoxycholic acid.]
[B01AB07, parnaparin, The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Ursodeoxycholic acid.]
[G03XB01, mifepristone, Ursodeoxycholic acid may decrease the excretion rate of Mifepristone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Ursodeoxycholic acid.]
[M02AA12, naproxen, Ursodeoxycholic acid may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[A10BX02, repaglinide, Ursodeoxycholic acid may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[B01AC17, tirofiban, The risk or severity of adverse effects can be increased when Tirofiban is combined with Ursodeoxycholic acid.]
[C09CA07, telmisartan, Ursodeoxycholic acid may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[C08CA04, nicardipine, Ursodeoxycholic acid may decrease the excretion rate of Nicardipine which could result in a higher serum level.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C08CA08, nitrendipine, Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XE01, nitrofurantoin, Ursodeoxycholic acid may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[G03DC02, norethindrone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Norethisterone.]
[G03AC07, norgestrienone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Norgestrienone.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AC16, eptifibatide, The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ursodeoxycholic acid.]
[B01AB08, reviparin, The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Ursodeoxycholic acid.]
[S02AA16, ofloxacin, Ursodeoxycholic acid may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Ursodeoxycholic acid.]
[B01AD09, ancrod, The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Ursodeoxycholic acid.]
[B01AB09, danaparoid, The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Ursodeoxycholic acid.]
[G03DB06, chlormadinone, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Chlormadinone.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ursodeoxycholic acid.]
[B01AA02, phenindione, The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Ursodeoxycholic acid.]
[N03AA02, phenobarbital, Phenobarbital may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Ursodeoxycholic acid.]
[C10AA05, atorvastatin, Ursodeoxycholic acid may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J05AE01, saquinavir, Ursodeoxycholic acid may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Ursodeoxycholic acid.]
[S01XA13, alteplase, The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Ursodeoxycholic acid.]
[A10BG02, rosiglitazone, Ursodeoxycholic acid may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[J05AE03, ritonavir, Ursodeoxycholic acid may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[C10AA08, pitavastatin, Ursodeoxycholic acid may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C10AB05, fenofibrate, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibrate.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ursodeoxycholic acid.]
[C01BA01, quinidine, Quinidine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[C03DA01, spironolactone, Ursodeoxycholic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
